Business
Akebia Announces Vadadustat Efficacy and Safety Data to be Presented at American Society of Nephrology Kidney Week 2021
CAMBRIDGE, Mass., Oct. 18, 2021 /PRNewswire/ -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA) today announced that vadadustat efficacy and safety data related to
About this update from Akebia Therapeutics, Inc.
[{"type":"text","content":"CAMBRIDGE, Mass., Oct. 18, 2021 /PRNewswire/ -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA) today announced that vadadustat efficacy and safety data related to clinical outcomes among patients with anemia due to chronic kidney disease (CKD) will be presented at the American Society of Nephrology Kidney Week 2021 (ASN Kidney Week), which is taking place virtually November 4 – November 7, 2021. Vadadustat is Akebia's investigational oral hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor, a potential first-in-class product in the U.S. for the treatment of anemia due to CKD, which is currently under review by the U.S. Food and Drug Administration with a scheduled Prescription Drug User Fee Act (PDUFA) date of March 29, 2022. \n\n \n \n \n \n \n \n\n \nAkebia will also present data on Auryxia® (ferric citrate), including a poster on the trial design of a collaborative clinical study on the use of Auryxia to prevent renal failure in adults with advanced CKD. All accepted vadadustat poster abstracts and other abstracts from Akebia are now available online on the ASN Kidney Week abstract portal: https://www.asn-online.org/education/kidneyweek/2021/program-search-abstract.aspx. \n\"We look forward to ASN as an opportunity to continue to share rich data on vadadustat with the nephrology community,\" said John P. Butler, Chief Executive Officer of Akebia Therapeutics. \"We believe these data demonstrate the efficacy and safety profile of vadadustat as a potential oral treatment for patients living with anemia due to chronic kidney disease.\"\nThe following abstracts have been accepted for presentation at ASN Kidney Week: \nVadadustat Presentations\nW. Winkelmayer, S. Fishbane, J. Tumlin, Y. Farag, W. Luo, R. Anders, C. Solinsky, D. Vargo, M. Koury\nIron-Related Outcomes in Patients with Dialysis-Dependent CKD Randomized to Vadadustat vs Darbepoetin Alfa\nPoster # PO0457\nM. Koury, P. Pergola, P. Roy-Chaudhury, Y. Farag, W. Luo, R. Anders, C. Solinsky, D. Vargo, W. Winkelmayer\nIron-Related Outcomes in Patients with Non–Dialysis-Dependent CKD Randomized to Vadadustat vs Darbepoetin Alfa\nPoster # PO0482\nR. Agarwal, D. Vargo, W. Luo, B. Maroni, C. Solinsky, G. Chertow\nComprehensive Safety Profile of Vadadustat from Global Phase 3 Clinical Trials\nPoster # PO0460\nG. Chertow, N. Boudville, P. Chowdhury, C. Gonzalez, L. Kooienga, ...